^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    B7-H3-targeted antibody-drug conjugate

    Related drugs:
    5d
    Ifinatamab deruxtecan, a B7-H3-directed antibody-drug conjugate, in patients with advanced solid tumours (IDeate-PanTumor01): dose-escalation results from a phase 1/2 trial. (PubMed, Lancet Oncol)
    The maximum tolerated dose was not reached with ifinatamab deruxtecan; however, one death due to treatment-related interstitial lung disease highlights the importance of prompt evaluation and careful management of patients who develop interstitial lung disease. Promising antitumour activity was observed across various solid tumours. These findings support further evaluation of ifinatamab deruxtecan in randomised controlled trials.
    P1/2 data • Journal • Pan tumor • First-in-human
    |
    CD276 (CD276 Molecule)
    |
    ifinatamab deruxtecan (DS-7300)
    5d
    SKB500-II-02: SKB500 Combinations in Patients With Small Cell Lung Cancer (clinicaltrials.gov)
    P2, N=80, Recruiting, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    carboplatin • etoposide IV • Cotelet (tagitanlimab)
    5d
    IDeate-Prostate01: A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (clinicaltrials.gov)
    P3, N=1440, Recruiting, Merck Sharp & Dohme LLC
    Trial initiation date
    |
    docetaxel • prednisone • ifinatamab deruxtecan (DS-7300)
    7d
    A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types (clinicaltrials.gov)
    P1, N=150, Recruiting, IDEAYA Biosciences
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CD276 (CD276 Molecule) • PTK7 (Protein Tyrosine Kinase 7)
    |
    HER-2 negative
    13d
    A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) (clinicaltrials.gov)
    P1/2, N=360, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2030 --> Apr 2031 | Trial primary completion date: Feb 2030 --> Apr 2031
    Trial completion date • Trial primary completion date
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • ifinatamab deruxtecan (DS-7300) • opevesostat (MK-5684)
    15d
    A Phase III Study Evaluating YL201 Versus ICC in 2L ESCC (clinicaltrials.gov)
    P3, N=440, Not yet recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.
    New P3 trial
    |
    paclitaxel • docetaxel • irinotecan • YL201
    19d
    BNT324-01: A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P1/2, N=594, Recruiting, BioNTech SE | N=112 --> 594
    Enrollment change
    |
    pumitamig (BNT327) • BNT324
    20d
    YL201-INT-102-02: A Study of YL201 in Combination with Other Anti-Cancer Therapies in Patients With Advanced Solid Tumors (2025-523742-27-00)
    P1/2, N=35, Not yet recruiting, Medilink Therapeutics (Suzhou) Co. Ltd.
    New P1/2 trial
    |
    Tecentriq (atezolizumab) • YL201
    22d
    A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) (clinicaltrials.gov)
    P1/2, N=262, Recruiting, Merck Sharp & Dohme LLC | N=59 --> 262
    Enrollment change
    |
    Imfinzi (durvalumab) • ifinatamab deruxtecan (DS-7300) • gocatamig (MK-6070)
    23d
    BNT324-01: A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer (clinicaltrials.gov)
    P1/2, N=112, Recruiting, BioNTech SE | N=82 --> 112
    Enrollment change
    |
    pumitamig (BNT327) • BNT324
    26d
    A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=280, Recruiting, Mabwell (Shanghai) Bioscience Co., Ltd.
    New P1/2 trial
    |
    cisplatin • carboplatin
    26d
    A Study YL201 in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=990, Active, not recruiting, MediLink Therapeutics (Suzhou) Co., Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    YL201